HUTCHMED (China) Limited
HCMHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong,. Valued at $2.45B, HCM is a mid-cap name in its sector. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Market Cap
$2.45B
Beta
0.45
P/E (TTM)
140.90
P/E (Fwd)
54.01
EPS (TTM)
$0.10
EPS (Fwd)
$0.26
ROE
1.5%
ROA
-1.2%
Cash
$1.38B
Total Debt
$94.5M
Free CF
-$18.9M
52W Change
-12.2%
Annual Financials
Cash vs Debt
Where HCM stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, HCM finished 4.32% below its 150-day moving average ($12.97) and 6.69% below its 200-day moving average ($13.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HCM overbought or oversold?
At the August 28, 2026 close, HCM's RSI(14) was 47.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.38B in cash comfortably exceeding the $94.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$18.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 1.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $426.4M to $548.5M.
With a beta below 0.7, HUTCHMED (China) Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. At over 50x earnings, HCM carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for HUTCHMED (China) Limited and its sector.